Lexicon Pharmaceuticals, Inc. (LXRX) financial statements and ratios from SEC XBRL: revenue $0.1B (TTM), net margin -101.1%, revenue growth 60.2% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $49.80M |
| Revenue (TTM) | $0.1B |
| Net Margin | -101.1% |
| Operating Margin (TTM) | -48.6% |
| Net Debt / EBITDA | -0.4 |
| Revenue Growth (YoY) | 60.2% |
| EPS Growth (YoY) | -77.8% |
| FCF Growth (YoY) | -62.3% |
| Price / Book | 5.89 |
| Price / Sales | 18.01 |
| FCF Yield | -4.9% |
| Altman Z-Score | -7.76 (distress) |
| Piotroski F-Score | 4/9 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Sector P/E (Healthcare) | 21.7 |
LXRX overview · LXRX earnings · LXRX KPIs · LXRX documents · LXRX ownership · LXRX peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.